Kelly John H, Lianov Liana, Shurney Dexter, Guimarães Sley Tanigawa, Palma Mechelle, Esselstyn Caldwell, Stoll Scott, Patel Padmaja, Rea Brenda, Reddy Koushik, Guthrie George, Reiss Michelle, Karlsen Micaela C
American College of Lifestyle Medicine, Chesterfield, MO, USA (JHK, BR, MCK).
School of Medicine, Loma Linda University, Loma Linda, CA, USA (JHK, BR, GG).
Am J Lifestyle Med. 2024 Feb 20;18(4):567-573. doi: 10.1177/15598276241230237. eCollection 2024 Jul-Aug.
The objective of this expert consensus process was to define performance measures that can be used to document remission or long-term progress following lifestyle medicine (LM) treatment.
Expert panel members with experience in intensive, therapeutic lifestyle change (ITLC) developed a list of performance measures for key disease states, using an established process for developing consensus statements adapted for the topic. Proposed performance measures were assessed for consensus using a modified Delphi process.
After a series of meetings and an iterative Delphi process of voting and revision, a final set of 32 performance measures achieved consensus. These were grouped in 10 domains of diseases, conditions, or risk factors, including (1) Cardiac function, (2) Cardiac risk factors, (3) Cardiac medications and procedures, (4) Patient-centered cardiac health, (5) Hypertension, (6) Type 2 diabetes and prediabetes, (7) Metabolic syndrome, (8) Inflammatory conditions, (9) Inflammatory condition patient-centered measures, and (10) Chronic kidney disease.
These measures compose a set of performance standards that can be used to evaluate the effectiveness of LM treatment for these conditions.
本专家共识制定过程的目的是确定可用于记录生活方式医学(LM)治疗后缓解情况或长期进展的绩效指标。
具有强化治疗性生活方式改变(ITLC)经验的专家小组成员,采用适合该主题的既定共识声明制定流程,制定了关键疾病状态的绩效指标清单。使用改良的德尔菲法对提议的绩效指标进行共识评估。
经过一系列会议以及投票和修订的迭代德尔菲过程,最终的32项绩效指标达成了共识。这些指标分为10个疾病、状况或风险因素领域,包括(1)心脏功能,(2)心脏风险因素,(3)心脏药物和手术,(4)以患者为中心的心脏健康,(5)高血压,(6)2型糖尿病和糖尿病前期,(7)代谢综合征,(8)炎症性疾病,(9)以炎症性疾病患者为中心的指标,以及(10)慢性肾脏病。
这些指标构成了一套绩效标准,可用于评估LM治疗这些疾病的有效性。